TY - JOUR
T1 - Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes
AU - Shafti-Keramat, Saeed
AU - Schellenbacher, Christina
AU - Handisurya, Alessandra
AU - Christensen, Neil
AU - Reininger, Bärbel
AU - Brandt, Sabine
AU - Kirnbauer, Reinhard
N1 - Funding Information:
This research was supported by a grant to RK from the FWF- Austrian Science Foundation (P18990-B13) and a grant to SB and RK by the Viennese Center of Innovation and Technology (ZIT). We thank Doug Lowy and John Schiller for critical reading of the manuscript.
PY - 2009/10/10
Y1 - 2009/10/10
N2 - Infection with bovine papillomavirus type 1 (BPV1) or BPV2 induces fibropapillomas in cows and skin sarcoids in horses. Prophylactic vaccination targeting BPV1 and BPV2 may reduce the incidence of these economically important diseases. The L1 major capsid proteins of BPV1 and BPV2 were expressed in Sf-9 insect cells and both self-assembled into virus-like particles (VLPs). Using conformation-dependent monoclonal antibodies (mAb) both type-specific and shared epitopes were detected. Antisera were raised against BPV1 or BPV2 VLP using alum adjuvant, and their (cross)neutralization capacity was tested by C127 neutralization assays using native BPV1 and BPV2 virions, or by BPV1 pseudovirion assay. Antisera induced by either VLP vaccine were able to robustly (cross-)neutralize heterologous as well as homologous types, indicating that BPV1 and BPV2 are closely related serotypes. These results suggest that a monovalent BPV1 (or BPV2) VLP vaccine may potentially protect against both BPV1 and BPV2 infections and associated diseases.
AB - Infection with bovine papillomavirus type 1 (BPV1) or BPV2 induces fibropapillomas in cows and skin sarcoids in horses. Prophylactic vaccination targeting BPV1 and BPV2 may reduce the incidence of these economically important diseases. The L1 major capsid proteins of BPV1 and BPV2 were expressed in Sf-9 insect cells and both self-assembled into virus-like particles (VLPs). Using conformation-dependent monoclonal antibodies (mAb) both type-specific and shared epitopes were detected. Antisera were raised against BPV1 or BPV2 VLP using alum adjuvant, and their (cross)neutralization capacity was tested by C127 neutralization assays using native BPV1 and BPV2 virions, or by BPV1 pseudovirion assay. Antisera induced by either VLP vaccine were able to robustly (cross-)neutralize heterologous as well as homologous types, indicating that BPV1 and BPV2 are closely related serotypes. These results suggest that a monovalent BPV1 (or BPV2) VLP vaccine may potentially protect against both BPV1 and BPV2 infections and associated diseases.
UR - http://www.scopus.com/inward/record.url?scp=70349238565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349238565&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2009.07.036
DO - 10.1016/j.virol.2009.07.036
M3 - Article
C2 - 19729180
AN - SCOPUS:70349238565
SN - 0042-6822
VL - 393
SP - 1
EP - 6
JO - Virology
JF - Virology
IS - 1
ER -
